Treatment of Pediatric Glioblastoma with Combination Olapariband Temozolomide Demonstrates 2-Year Durable Response

ANDGE, V.; GORELYSHEV, S.; KONOVALOV, A.; TRUNIN, Y.; SAVATEEV, A.; E, K.D.; SEVERSON, E.; HEMMERICH, A.; EDGERLY, C.; DUNCAN, D.; BRITT, N.; H.R.; ELVIN, J.; MILLER, V.; S, R.J.; GAY, L.; MCCORKLE, J.; RANKIN, A.; L, E.R.; CHUDNOVSKY, Y.; H, R.S.

Авторы: ANDGE VALIAKHMETOVA, SERGEY GORELYSHEV, ALEXANDER KONOVALOV, YURI TRUNIN, ALEXANDER SAVATEEV, KRAM DAVID E., ERIC SEVERSON, AMANDA HEMMERICH, CLAIRE EDGERLY, DANIEL DUNCAN, NICHOLAS BRITT, HUANG RICHARD S.P, JULIA ELVIN, VINCENT MILLER, ROSS JEFFREY S., LAURIE GAY, JOSHUA MCCORKLE, ANDREW RANKIN, ERLICH RACHEL L., YAKOV CHUDNOVSKY, RAMKISSOON SHAKTI H.
Журнал: The Oncologist
Том: 24
Номер: 10
Год издания: 2019
Первая страница: 1
Последняя страница: 5
DOI: 10.1634/theoncologist.2019-0603
Аннотация: For pediatric patients with high-grade gliomas, standard-of care treatment includes surgery, chemotherapy, and radiation therapy; however, most patients ultimately succumb to their disease. With advances in genomic characterization of pediatric high-grade gliomas, the use of targeted therapies in combination with current treatment modalities offer the potential to improve survival in this patient population. In this report, we present the case of a 3-year-oldgirlwithglioblastomawho continues to experience an exceptional and durable response (>2 years) to the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib. Our patient presented with persistent and progressive seizure activity that upon workup was the result of a large heterogeneously enhancing, mixed cystic and solid mass in the left frontal-parietal-temporal region. Histopathologic analysis of resected tumor tissue conﬁrmed the diagnosis of glioblastoma, and comprehensive genomic proﬁling demonstrated absence of any BRAF or H3F3A mutations. Genomic proﬁling, however, did reveal a probable germline heterozygous BRCA2 Lys3326Ter (K3226*) nonsense variant. After debulking surgery, the patient received standard-of-care treatment with radiation and temozolomide. Nine months later the PARP inhibitor olaparib was administered in combinationwithtemozolomidefor16cycles.This regimen was well tolerated by the patient and serial imaging showed reduction in tumor size. Since completion of the regimen, the patient remains neurologically intact with no evidence of tumor recurrence. To our knowledge, this represents the ﬁrst case of a pediatric glioblastoma that maintains a durable response to a therapeutic strategy that included the PARP inhibitor olaparib and more generally highlights the potential clinical utility of incorporating these agents into the treatment of pediatric high-grade gliomas.TheOncologist2019;24:1–5
Добавил в систему: Валиахметова Эндже Фаварисовна

	ИСТИНА	Войти в систему Регистрация
	ИСТИНА ИНХС РАН
	Главная Поиск Статистика О проекте Помощь

ИСТИНА

ИСТИНА ИНХС РАН

Treatment of Pediatric Glioblastoma with Combination Olapariband Temozolomide Demonstrates 2-Year Durable Responseстатья Исследовательская статья